Trade XBiotech Inc. - XBIT CFD
Add to favourite- Summary
- Historical Data
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 6.96 |
Open | 6.66 |
1-Year Change | 27.83% |
Day's Range | 6.66 - 7.19 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jul 25, 2024 | 6.98 | 0.72 | 11.50% | 6.26 | 6.99 | 6.08 |
Jul 24, 2024 | 6.18 | -0.24 | -3.74% | 6.42 | 6.48 | 5.97 |
Jul 23, 2024 | 6.23 | 0.18 | 2.98% | 6.05 | 6.39 | 6.05 |
Jul 22, 2024 | 6.09 | 0.14 | 2.35% | 5.95 | 6.15 | 5.94 |
Jul 19, 2024 | 5.95 | -0.41 | -6.45% | 6.36 | 6.47 | 5.78 |
Jul 18, 2024 | 6.68 | 0.25 | 3.89% | 6.43 | 6.88 | 6.43 |
Jul 17, 2024 | 6.56 | 0.24 | 3.80% | 6.32 | 6.65 | 6.14 |
Jul 16, 2024 | 6.54 | 0.49 | 8.10% | 6.05 | 6.62 | 6.03 |
Jul 15, 2024 | 6.19 | 0.16 | 2.65% | 6.03 | 6.51 | 6.03 |
Jul 12, 2024 | 6.16 | -0.27 | -4.20% | 6.43 | 6.72 | 6.04 |
Jul 11, 2024 | 6.60 | 0.37 | 5.94% | 6.23 | 6.69 | 6.23 |
Jul 10, 2024 | 6.25 | 0.48 | 8.32% | 5.77 | 6.56 | 5.69 |
Jul 9, 2024 | 5.90 | 0.18 | 3.15% | 5.72 | 6.00 | 5.66 |
Jul 8, 2024 | 5.78 | 0.65 | 12.67% | 5.13 | 5.90 | 5.03 |
Jul 5, 2024 | 5.68 | -0.04 | -0.70% | 5.72 | 5.82 | 5.57 |
Jul 3, 2024 | 5.70 | 0.02 | 0.35% | 5.68 | 5.85 | 5.60 |
Jul 2, 2024 | 5.66 | 0.30 | 5.60% | 5.36 | 5.93 | 5.21 |
Jul 1, 2024 | 5.53 | 0.72 | 14.97% | 4.81 | 5.53 | 4.78 |
Jun 28, 2024 | 5.07 | 0.57 | 12.67% | 4.50 | 5.49 | 4.44 |
Jun 27, 2024 | 4.57 | -0.37 | -7.49% | 4.94 | 4.94 | 4.20 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
XBiotech Inc. Company profile
About XBiotech Inc
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases. The Company is engaged in the development of biotech manufacturing technologies designed to flexibly produce therapies. It has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. It has also developed commercial scale manufacturing technology that reduces the time to launch new product candidates. It is focused on the therapies that block a potent substance naturally produced by body, known as interleukin-1 alpha (IL-1a), that mediates tissue breakdown, angiogenesis, the formation of blood clots and inflammation. IL-1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma. The Company's True Human antibody therapeutics are developed in-house using its discovery platform.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, XBiotech Inc revenues decreased 58% to $18.4M. Net loss increased 55% to $17.4M. Revenues reflect Clinical trial service revenue decrease of 98% to $394K, Other revenue decrease from $22K to $0K. Higher net loss reflects Research and Development increase from $3.3M to $14M (expense), Salaries and related expenses increase from $2.6M to $12.2M (expense).
Industry: | Bio Therapeutic Drugs |
5217 Winnebago Lane
AUSTIN
TEXAS 78744
US
News
![](https://img.capital.com/imgs/articles/192x130x1/Risk-Management-in-Trading.png)
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ECB_0.png)
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024![](https://img.capital.com/imgs/articles/192x130x1/risk_2_1_optimized_450_1.png)
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024![](https://img.capital.com/imgs/articles/192x130x1/Stock-1-_1.png)
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ETF-1-_0.png)
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024![Lloyds share price forecast: An attractive dividend stock? Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/192x130x1/shutterstock_536730610_0.jpg)
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024![](https://img.capital.com/imgs/articles/192x130x1/RBNZ.png)
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com